• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J launches fourth large-scale COVID-19 vaccine trial

J&J launches fourth large-scale COVID-19 vaccine trial

September 23, 2020 By Sean Whooley

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) has begun enrollment of adult volunteers for a fourth Phase 3 clinical trial of a COVID-19 vaccine candidate.

The National Institutes of Health announced today that J&J’s Janssen Pharmaceuticals COVID-19 vaccine candidate (JNJ-78436725) has begun the Phase 3 trial to evaluate if it can prevent symptomatic COVID-19 after a single dose regimen.

Up to 60,000 volunteers are slated to be enrolled in the trial, which will take place across up to nearly 215 clinical research sites in the U.S. and across the globe, according to an NIH news release. Janssen is leading the trial as a regulatory sponsor with funding from National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and the Biomedical Advanced Research and Development Authority (BARDA).

Last month, the U.S. Dept. of Health and Human Services and Defense Dept. agreed to a $1 billion deal for the Janssen candidate, as the J&J subsidiary is set to offer large-scale manufacturing and the delivery of the vaccine, with the federal government owning 100 million doses.

“Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified,” NIAID Director Dr. Anthony Fauci said in the release. “This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry and academia. It is likely that multiple COVID-19 vaccine regimens will be required to meet the global need.

“The Janssen candidate has showed promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose.”

Janssen’s candidate is a recombinant vector vaccine using a human adenovirus to express the SARS-CoV-2 spike protein in cells. It uses the same vector in the first dose of its prime-boost vaccine regimen against Ebola, which recently received European commercial approval.

Preclinical findings for the vaccine candidate demonstrated that it induced neutralizing antibody responses in rhesus macaques and offered complete or near-complete protection against the virus infection in the lungs nad nose. The candidate’s safety, reactogenicity and immunogenicity are being evaluated in a Phase 1/2a trial in the U.S. and Belgium, with interim results supporting further development.

The Phase 3 trial is operating in collaboration with the U.S. government’s “Operation Warp Speed” initiative that seeks to provide a safe vaccine by the end of 2020, with Janssen joining vaccine candidate developers Moderna (NSDQ:MRNA) and AstraZeneca (NYSE:AZN) under the operation’s umbrella. Pfizer (NYSE:PFE) and BioNTech’s (NSDQ:BNTX) vaccine candidate is the fourth one to reach Phase 3 clinical trials.

“To have just one candidate vaccine in Phase 3 trials less than a year after a virus was first reported would be a remarkable accomplishment; to have four candidates at that stage is extraordinary,” HHS Secretary Alex Azar said. “By building a portfolio of candidate vaccines, Operation Warp Speed is maximizing the chances that we will have substantial supplies of a safe and effective vaccine—and maybe multiple vaccine options—by January 2021.”

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Dept. of Health & Human Services (HHS), Janssen Pharmaceuticals, Johnson and Johnson, National Institutes of Health (NIH), U.S. Biomedical Advanced Research and Development Authority (BARDA)

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy